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Activation of the Interferon Induction Cascade by Influenza A Viruses
Requires Viral RNA Synthesis and Nuclear Export
Marian J. Killip, Matt Smith, David Jackson, Richard E. Randall
School of Biology, Biomedical Sciences Research Complex, North Haugh, University of St. Andrews, St. Andrews, Fife, United Kingdom
ABSTRACT
We have examined the requirements for virus transcription and replication and thus the roles of input and progeny genomes in
the generation of interferon (IFN)-inducing pathogen-associated molecular patterns (PAMPs) by influenza A viruses using in-
hibitors of these processes. Using IFN regulatory factor 3 (IRF3) phosphorylation as a marker of activation of the IFN induction
cascade that occurs upstream of the IFN- promoter, we demonstrate strong activation of the IFN induction cascade in A549
cells infected with a variety of influenza A viruses in the presence of cycloheximide or nucleoprotein (NP) small interfering RNA
(siRNA), which inhibits viral protein synthesis and thus complementary ribonucleoprotein (cRNP) and progeny viral RNP
(vRNP) synthesis. In contrast, activation of the IFN induction cascade by influenza viruses was very effectively abrogated by
treatment with actinomycin D and other transcription inhibitors, which correlated with the inhibition of the synthesis of all vi-
ral RNA species. Furthermore, 5,6-dichloro-1--D-ribofuranosyl-benzimidazole, an inhibitor that prevents viral RNA export
from the nucleus, was also a potent inhibitor of IRF3 activation; thus, both viral RNA synthesis and nuclear export are required
for IFN induction by influenza A viruses. While the exact nature of the viral PAMPs remains to be determined, our data suggest
that in this experimental system the major influenza A virus PAMPs are distinct from those of incoming genomes or progeny
vRNPs.
IMPORTANCE
The host interferon system exerts an extremely potent antiviral response that efficiently restricts virus replication and spread;
the interferon response can thus dictate the outcome of a virus infection, and it is therefore important to understand how viruses
induce interferon. Both input and progeny genomes have been linked to interferon induction by influenza viruses. However, our
experiments in tissue culture cells show that viral RNA synthesis and nuclear export are required to activate this response. Fur-
thermore, the interferon induction cascade is activated under conditions in which the synthesis of progeny genomes is inhibited.
Therefore, in tissue culture cells, input and progeny genomes are not the predominant inducers of interferon generated by influ-
enza A viruses; the major viral interferon inducer(s) still remains to be identified.
The genome of influenza A viruses (IAVs) is carried by eightsegments of negative-sense viral RNA (vRNA). Each vRNA
segment is separately packaged into viral ribonucleoprotein
(vRNP), in which it is associated with viral nucleoprotein (NP)
and the viral polymerase complex. These vRNPs form helical
structures in which the 3= and 5= termini are held in a closed
conformation by the viral polymerase, while the remainder of the
length of the RNA is encapsidated by multiple monomers of NP
(reviewed in reference 1). The viral polymerase is responsible for
both the transcription and replication of vRNPs, which occur in
the nuclei of infected cells, unlike most other RNA viruses. The
polymerase generates viral mRNA transcripts using vRNPs as a
template; this process requires the polymerase cap-snatching ac-
tivity to cleave 10- to 15-nucleotide (nt) RNA fragments from the
5= ends of cellular pre-mRNAs that function as primers for viral
mRNA synthesis. In addition, a polyuridine stretch at the 5= end of
each genome segment directs the polyadenylation of viral tran-
scripts. To replicate the virus genome, the viral polymerase first
synthesizes cRNA, the full-length complement of vRNA, which is
packaged into complementary RNPs (cRNPs); cRNPs function as
a replicative intermediate that directs the synthesis of large num-
bers of progeny vRNPs, from which secondary transcription can
occur prior to their nuclear export and assembly into progeny
virions.
The interferons (IFNs) are a family of cytokines produced in
response to virus infection that can potentially exert powerful an-
tiviral effects through the upregulation of many different interfer-
on-stimulated genes (ISGs) in both infected cells and neighboring
uninfected cells. Thus, the IFN response very effectively restricts
virus replication and spread (reviewed in reference 2), and as a
result, most viruses encode antagonists of this response. For influ-
enza viruses, the principal IFN antagonist is the small multifunc-
tional NS1 protein that targets the IFN system at multiple stages
(reviewed in references 3 and 4). IFN is induced during RNA virus
infections through the detection of viral pathogen-associatedmo-
lecular patterns (PAMPs) by cellular pathogen recognition recep-
tors (PRRs). The principal PRRs involved in detecting RNA virus
infections are the cytosolic RNA helicases RIG-I and MDA-5;
PAMP binding to these receptors activates a downstream signal-
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ing pathway that culminates in the activation and nuclear trans-
location of the ATF2/c-Jun, NF-B, and IFN regulatory factor 3
(IRF3) transcription factors and subsequent transcription from
the IFN- promoter. IFN induction by influenza A viruses is
thought to occur primarily through RIG-I activation (5–7).Much
previous work has been carried out in order to characterize the
RNA ligands capable of activating RIG-I in vitro; it is now gener-
ally thought that RIG-I activation requires short blunt-ended
double-stranded RNA (dsRNA) with a free 5=ppp group (re-
viewed in reference 8), although single-stranded RNA with com-
plementary termini that can form panhandle structures contain-
ing small stretches of dsRNA are also able to activate RIG-I (9, 10).
It has therefore been suggested that base pairing between the par-
tially complementary 3= and 5= termini of the influenza virus ge-
nome is responsible for RIG-I activation by this virus (7, 11),
although the requirement for bound viral polymerase in themain-
tenance of this base pairing (12) may preclude RIG-I binding to
the genome termini. The nature of the viral RNA that associates
with RIG-I during influenza virus infections has previously been
examined by deep sequencing (7); in that study, RIG-I was found
to associate with sequences mapping to subgenomic viral RNAs
(associated with defective viruses) and the shorter genome seg-
ments. However, since all RNA species that immunoprecipitated
with RIG-I were sequenced in this analysis, no distinction was
made as to whether these RNAs were vRNA, cRNA, or mRNA.
The relative contributions of virus replication and transcription to
IFN induction by influenza virus were examined in another study
using vRNP reconstitution experiments (11); here, it was reported
that IFN induction required progeny vRNA synthesis but not vi-
rus transcription. The ability of progeny genomes to induce IFN
has not been demonstrated within infected cells, however, and it
therefore remains unclear whether input or progeny genomes or
indeed another RNA species generated during infection is pre-
dominantly responsible for IFN induction during virus infection.
In this regard, it is possible that several different types of PAMPare
generated or exposed in infected cells, and their relative contribu-
tions to overall IFN induction during a virus infection may vary
considerably.
In this study, we have examined the effects of several inhibitors
of viral polymerase replication and/or transcription activities on
activation of the IFN induction cascade in A549 cells and corre-
lated this with the effects of these inhibitors on viral RNA synthe-
sis; this analysis permitted us to determine the contributions of
input and progeny virus genomes to IFN induction within in-
fected cells. We demonstrate that for several different influenza
viruses, strong activation of the IFN induction cascade can occur
under conditions in which viral replication is inhibited. We also
demonstrate that input vRNPs do not function as PAMPs since
activation of the IFN induction cascade was sensitive to drugs that
inhibited both viral transcription and replication. Thus, a major
PAMP responsible for IFN induction by influenza A viruses in this
experimental system requires viral RNA synthesis, but not ge-
nome replication, for its generation.
MATERIALS AND METHODS
Cells and inhibitors. A549, MRC-5, andMDCK cells (all from the Euro-
pean Collection of Cell Cultures [ECACC]) and their derivatives were
grown as monolayers in Dulbecco’s modified Eagle’s medium (DMEM)
supplementedwith 10% fetal bovine serum (FBS) at 37°C. Cycloheximide
(CHX; used at 50 g/ml), actinomycin D (ActD; used at 1 g/ml), or
5,6-dichloro-1--D-ribofuranosyl-benzimidazole (DRB; 250 M) was
added to the medium at the time of infection, as indicated. Alpha-amani-
tin was used at 20g/ml and required a 1-h period of pretreatment before
virus infection in order to efficiently inhibit viral protein synthesis (data
not shown). Poly(I·C) transfections were carried out as described else-
where (13). Small interfering RNA (siRNA) transfections were carried out
using DharmaFECT (Thermo Scientific) according to themanufacturer’s
instructions. The sequences of NP-1496 and NP-231 siRNAs and their
effects on influenza virus replication have been described previously (14)
and were synthesized by Thermo Scientific. ON-TARGETplus Non-Tar-
geting Pool (Thermo Scientific) was used as nontarget control siRNA.
Virus infections.The influenza A virus stocks of A/Udorn/72 (H3N2)
(Ud), A/PR/8/34 (H1N1) (PR8), and A/WSN/33 (H1N1) (WSN) were
generated by a low multiplicity of infection (MOI; 0.001 PFU/cell) in
MDCK cells in serum-free DMEM supplemented with 2 g/ml N-acetyl
trypsin (Sigma) at 37°C. Viruses were titrated on MDCK cells as previ-
ously described (15). Recombinant NS1mutant viruses Ud-99 (15) and
PR8-NS1 (16) were grown and titrated in IFN-defective MDCK cells
expressing PIV5/V and BVDV/NPro (17, 18) or PR8/NS1 and BVDV/
NPro, respectively. PIV5-VCvM2was generated as previously described
(19, 20), and Sendai virus (SeV)Cantell was purchased fromCharles River
Laboratories. Virus infections were carried out at the indicated multiplic-
ities of infection in serum-free DMEM in the absence of trypsin.
Immunoblotting and immunofluorescence. The procedures for im-
munoblotting and immunofluorescence have been described previously
(21, 22). Antibodies used for immunoblotting in this study included
monoclonal antibodies raised against phospho-IRF3 (Cell Signaling
Technology) and -actin (Sigma) and polyclonal antibodies against total
IRF3 (Santa Cruz) and ISG56 (Santa Cruz). Influenza virus NP and M1
proteins were detected using sheep antisera raised against purified and
disrupted X31 virus, while NS1 was detected using purified antisera pro-
duced against PR8NS1 (both antisera produced byDiagnostics Scotland).
In immunofluorescence studies, anti-IRF3 (Santa Cruz) and anti-p65
(Cell Signaling) antibodies were used. Immunofluorescence was exam-
ined using a Zeiss LSM 5 Exciter confocal microscope.
In situ hybridization. Probes against NPmRNA for in situ hybridiza-
tion were generated from linearized pcDNA-NP, a plasmid containing a
cDNA copy of PR8 segment 5 (23) (a kind gift from P. Digard, University
of Edinburgh), using a digoxigenin (DIG) RNA labeling kit (Roche) ac-
cording to the manufacturer’s instructions. A549 monolayers (seeded
onto poly-L-lysine-treated coverslips) were infected and/or treated with
drugs as indicated. At the desired time postinfection, coverslips were
washed with phosphate-buffered saline (PBS), fixed in PBS–5% formal-
dehyde for 15 min, and then washed twice in PBS for 5 min. Cells were
treated with 2g/ml proteinase K (in 20mMTris [pH 7.5]–2mMCaCl2)
at 37°C for 10 min and then rinsed twice in PBS–0.1% Tween 20. Cells
were postfixed for 15 min at room temperature (RT) in PBS–5% formal-
dehyde followed by permeabilization in PBS–0.5% Triton X-100 supple-
mentedwith 2mMvanadyl ribonucleoside complexes (Sigma) for 15min
at RT with gentle shaking. Coverslips were washed three times in PBS for
5 min at RT followed by incubation with a hybridization mixture (50%
deionized formamide, 1 Tris-EDTA [TE], 300 mM NaCl, 1 Den-
hardt’s solution, 1 mM dithiothreitol [DTT], 1 U/l RNasin, 5% dextran
sulfate [wt/vol], 500g/ml tRNA, 200g/ml salmon spermDNA) for 1 h
at 55°C. During this period, labeled probe (100 ng per coverslip) in the
hybridization mixture was heated to 95°C for 5 min, followed by quench-
ing on ice for 10 min. Coverslips were incubated overnight with this
probe-hybridizationmixture at 55°C in a humidified chamber. Following
hybridization, coverslips were sequentially washed with 2 SSC–10 mM
Tris (pH7.5) (15min at RT) (1 SSC is 0.15MNaCl plus 0.015Msodium
citrate), 0.1 SSC–10 mM Tris (pH 7.5) (15 min at RT), 30% deionized
formamide–0.1 SSC–10 mM Tris (pH 7.5) (30 min at 55°C), and 0.1
SSC–10mMTris (pH 7.5) (5min at RT). Bound probewas detected using
alkaline phosphatase-conjugated anti-DIG antibody (Roche) and Fast
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Red tablets (Roche). Fast Red fluorescence was examined with a Zeiss
LSM 5 Exciter confocal microscope.
Primer extension analysis. RNA was extracted from infected cells
using TRIzol (Invitrogen), and the levels of vRNA, cRNA, and mRNA
were examined by primer extension analyses as described previously (24).
[-32P]ATP (PerkinElmer) was used to radioactively label oligonucleo-
tides (IDT) complementary to positive- and negative-sense PR8 viral
RNA transcripts specific for the NP segment using T4 polynucleotide
kinase (Thermoscientific) according to the manufacturer’s instruc-
tions (5=-CGTTCTCCATCAGTCTCCATCTGTTCG-3= and 5=-GATG
TGTCTTTCCAGGGGCGGG-3=, respectively). A further primer com-
plementary to cellular 5S RNAwas included to demonstrate equal loading
(25). Labeled oligonucleotides were annealed to total cellular RNA iso-
lated as described and subsequently reverse transcribed to labeled cDNA
using Superscript II at 45°C (Life Technologies). To terminate this reac-
tion, the contents were mixed 1:1 with formamide loading buffer and
boiled. The samples were then loaded onto a denaturing polyacrylamide
gel (7 M urea–6% 19:1 polyacrylamide:bis acrylamide) and run in 1
Tris-borate-EDTA (TBE) buffer. Transcript levels were determined by
autoradiography and read on a Fujifilm FLA5000 phosphorimager.
RESULTS
Activation of the IFN induction cascade by influenza A viruses
can occur when virus protein synthesis and the generation of
progeny vRNPs are inhibited. First, the requirement for virus
protein synthesis and genome replication in the activation of the
IFN induction cascade by influenza A viruses was examined. De
novo NP synthesis and concurrent assembly of nucleocapsids are
required for replication of the IAV genome; consequently, by
blocking NP synthesis, the translational elongation inhibitor cy-
cloheximide (CHX) prevents viral replication by inhibiting cRNP
and progeny vRNP generation and thus secondary transcription
(24, 26–29) (see Fig. 6A). A549 cells were infected with several
different influenza A viruses in the presence or absence of CHX
and cell lysates were probed for the presence of the active, phos-
phorylated form of IRF3 as a marker of activation of the IFN
induction cascade. IRF3 activation occurs prior to transcription
from the IFN- promoter and can thus be used to detect activa-
tion of the IFN induction cascade under conditions where cellular
protein synthesis is blocked. The phosphorylated form of IRF3
was barely detectable following infection with the influenza virus
strains A/WSN/33 (H1N1) (WSN) and A/PR/8/34 (H1N1) (PR8)
in untreated cells, while A/Udorn/72 (H3N2) (Ud) induced small
amounts of IRF3 phosphorylation (Fig. 1A and B). In contrast,
infection with all three of these virus strains resulted in consider-
able IRF3 activation under CHX treatment conditions in which
virus protein synthesis was very efficiently inhibited. To confirm
that IRF3 activation occurred in the absence of virus protein syn-
thesis, we used an siRNA approach to inhibit viral NP expression.
This has previously been shown to inhibit cRNA and vRNA syn-
thesis and indirectly leads to inhibition of the synthesis of all virus
proteins by abrogating secondary transcription (14) (Fig. 1C).
Treatment of cells with NP-1496 siRNA led to a very efficient
knockdown of NP protein synthesis and also inhibited the expres-
sion of other viral proteins, as indicated by a lack of hemagglutinin
(HA) synthesis in NP-1496-treated cells (Fig. 1C). This efficient
knockdown of viral protein synthesis correlated with a clear in-
crease in IRF3 activation by Ud virus compared to untreated cells,
consistent with the results obtained using CHX (Fig. 1A). IRF3
activation was not observed following siRNA-mediated knock-
down of NP expression from a transfected plasmid (data not
shown), so this effect was specific to the knockdown ofNP expres-
sion from infecting virus. In contrast, an additional NP siRNA,
NP-231, was unable to effectively inhibit NP and HA synthesis
under these treatment conditions; this siRNA subsequently had
no effect on IRF3 activation by Ud virus. Together, these results
suggest that virus protein synthesis and thus the synthesis of prog-
eny vRNPs are not essential for activation of the IFN induction
cascade by influenza viruses; indeed, IRF3 activation is actually
considerably enhanced under conditions (e.g., CHX treatment
and NP siRNA knockdown) in which these processes are inhib-
ited.
We hypothesized that the higher levels of IRF3 phosphoryla-
tion in CHX-treated cells than in untreated cells infected with
influenza A viruses was due to inhibition of expression of NS1 by
CHX and thus alleviation of its IFN-inhibitory effects. To address
this, we examined IRF3 activation in the presence of CHX by two
viruses that lack a fully functionalNS1 protein and are thus unable
to effectively antagonize IFN induction: Ud-99, a recombinant
Ud virus that lacks most of the effector domain of NS1 (15), and
PR8-NS1, in which the entire NS1 gene has been deleted (16). As
FIG 1 IRF3 activation by influenza A viruses in the absence of virus protein
synthesis. (A and B) A549monolayers were infected withUd (A),WSN (A), or
PR8 (B) at 5 PFU/cell or left uninfected (UI) for 8 h in the presence or absence
of CHX. Cell lysates were prepared and subjected to SDS-PAGE and immu-
noblotting for phospho-IRF3 (p-IRF3), total IRF3, viral NP, and actin. Note
that inputNP could be detected underCHX treatment conditions upon longer
exposures. (C) A549 cells were transfected with no siRNA () or 25 mM
nontarget (NT) orNP-specificNP-1496 orNP-231 siRNAs for 24 h. Cells were
infected with Ud (5 PFU/cell) for a further 8 h, and then cell lysates were
prepared and subjected to SDS-PAGE and immunoblotting for phospho-IRF3
(p-IRF3), total IRF3, viral NP and HA, and actin. Note that only NP-1496
siRNA efficiently inhibited NP expression in A549 cells. (D and E) A549
monolayers were infected with Ud-99 (D) or PR8-NS1 (E) at 5 PFU/cell or
left uninfected for 8 h in the presence or absence of CHX, and lysates were
treated as described above.
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predicted, both Ud-99 (Fig. 1D) and PR8-NS1 (Fig. 1E) in-
duced considerable IRF3 phosphorylation in untreated cells, con-
sistent with the loss of NS1 function leading to enhanced activa-
tion of the IFN response compared to the parental wild-type (wt)
viruses. Similar levels of IRF3 phosphorylation were detected in
Ud-99-infected cells in the presence or the absence of CHX. This
is in contrast to the obvious increase in IRF3 activation seen in
Ud-wt-infected cells upon CHX treatment. Thus, the very weak
activation of IRF3 during wt infections is most likely due to NS1
inhibiting activation of the IFN induction cascade. That we ob-
serve no reduction in IRF3 activation by Ud-99 in cells treated
with CHX compared to untreated cells strongly suggests that un-
der these conditions progeny vRNA genomes are not responsible
for activating the IFN induction cascade. In contrast to the IRF3
activation profile seen with Ud-99, CHX treatment reduced the
levels of IRF3 activation by PR8-NS1 compared to those seen in
untreated infected cells. This was not necessarily indicative of an
absolute requirement for virus replication in order to activate the
IFN induction cascade, however, since IRF3 activation could still
be detected under CHX treatment conditions for both PR8-NS1
and the parental PR8 virus (Fig. 1B and E). Furthermore, increas-
ing the multiplicity of infection for PR8-NS1 considerably in-
creased the levels of IRF3 activation in the presence of CHX rela-
tive to the amount in untreated infected cells (data not shown; see
also Fig. 3E).
To determine whether activation of IRF3 by influenza A vi-
ruses in the absence of virus replication also correlated with the
transcription of IRF3-responsive genes, a CHX reversal experi-
ment was performed. Cells were infected in the presence of CHX
(during which time protein synthesis is inhibited but the accumu-
lation ofmRNA transcripts is unaffected) and then reversed in the
presence of actinomycinD (ActD) (which forms stable complexes
with DNA to inhibit DNA-dependent RNA synthesis); under
these conditions, transcripts that have accumulated in the pres-
ence of CHX can be translated, while ActD prevents further cellu-
lar transcription. IRF3-responsive gene products expressed under
these CHX reversal conditions must therefore have been synthe-
sized from transcripts that accumulated in the presence of CHX
treatment (and therefore in the absence of viral protein synthesis
and genome replication). In accordance with the IRF3 activation
by influenza A viruses observed in the presence of CHX (Fig. 1),
we could detect expression of the IRF3-responsive gene product
ISG56 under CHX reversal conditions (Fig. 2). Clearly, then, ac-
tivation of the IFN induction cascade and transcription from
IRF3-responsive antiviral genes can occur in A549 cells in the
absence of virus protein synthesis and therefore in the absence of
progeny vRNP generation.
Actinomycin D inhibits activation of the IFN induction cas-
cade by influenza A viruses. The data presented above indicated
that progeny vRNPs are not required for activation of the IFN
induction cascade by influenza A virus, but it remained unclear
whether input vRNPs were sufficient to induce IFN. While CHX
impairs cRNA and vRNA synthesis by the viral polymerase, it does
not prevent accumulation of viral mRNA transcripts, although
secondary viral transcription is impaired by CHX due to a reduc-
tion in available vRNA templates (24) (see Fig. 6A). Influenza A
virus transcription by the viral polymerase requires cellular pre-
mRNAs to provide 5=-capped primers for transcription initiation
(30, 31); consequently, influenza A virus replication is sensitive to
inhibitors of cellular transcription (28, 32). Thus, following treat-
ment with ActD, primary viral transcription is blocked and no
viral mRNA can be detected in infected cells (33, 34) (see Fig. 6).
To determine whether the input virus genome alone was a major
activator of the IFN induction cascade or whether viral polymer-
ase activity was required for IFN induction, we examined IRF3
activation in A549 cells treated with ActD. Strikingly, IRF3 activa-
tion could not be detected following infection with any of our
panel of influenza viruses (Ud, Ud-99, WSN, PR8, and PR8-
NS1) in the presence of ActD (Fig. 3). This was a stark difference
from the situation following CHX treatment (which often consid-
erably enhanced IRF3 activation), despite both ActD and CHX
efficiently inhibiting the expression of viral proteins, including
NS1. This inhibition of IRF3 activation by ActD was observed
even when the multiplicity of infection was considerably in-
creased; while	50 PFU/cell PR8-NS1 induced substantial levels
of phospho-IRF3 in untreated and CHX-treated A549 cells, neg-
ligible IRF3 activation was detectable in ActD-treated infected
cells (Fig. 3E). This effect of ActD was not cell-type specific, since
ActD also inhibited influenza-virus-induced IRF3 activation in
MDCK and untransformed lung fibroblast MRC-5 cells (Fig. 3F).
Inhibition of influenza-virus-induced IRF3 activation by ActD
was not due to nonspecific effects of the drug on the activation of
the IFN induction cascade, since, importantly, ActD did not in-
hibit IRF3 activation by the synthetic dsRNA analogue poly(I·C)
or by PIV5-VC vM2 (35), a preparation of parainfluenza virus 5
(a virus insensitive to cellular transcription inhibitors [36]) that is
an efficient IFN inducer due to the presence of defective viruses
(Fig. 4A). Furthermore, ActD had no effect on IRF3 activation by
the Cantell stock of Sendai virus (Fig. 4B), a defective virus-rich
preparation that is well characterized as a RIG-I activator (7, 37,
38), indicating that ActD does not inhibit RIG-I activation in gen-
eral but that its effects are specific to influenza virus. In addition,
the inability of influenza A virus to activate IRF3 in ActD-treated
cells was not due to impairment of virus entry and RNP import to
the nucleus by this drug, since the nuclear localization of input
vRNPs was unaffected by ActD treatment (Fig. 4C).
As an additional measure of activation of the IFN induction
cascade, we examined the effects of ActD on the nuclear translo-
cation of both IRF3 and the p65 subunit of NF-
B, a step that
occurs following activation of these transcription factors in the
cytoplasm. A549 cells were infected with Ud or PR8-NS1 in the
presence of ActD or no drug for 8 h, after which time cell mono-
layers were fixed and stained for IRF3 and p65 localization. The
resulting confocal microscopy images are shown in Fig. 5, and the
percentage of cells exhibiting nuclear localization of these tran-
FIG2 Influenza A viruses induce transcription from IRF3-responsive genes in
the absence of virus protein synthesis. A549 cells were infectedwith PR8-NS1
as indicated in the presence of CHX. At 8 h postinfection (p.i.), monolayers
were washed in ActD-containing medium and incubated in the presence of
ActD for a further 4 h (C/A). As controls, cells were left untreated () or were
incubated for 12 h in CHX (C) or ActD (A). Cells were harvested at 12 h p.i.
Cell lysates were prepared and subjected to SDS-PAGE and immunoblotting
for ISG56 and actin.
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scription factors under each treatment/infection condition is in-
dicated. In the absence of drug, nuclear IRF3 was detectable in
8.8% and 35.8% of cells following infection with Ud or PR8-
NS1, respectively. Similar levels of p65 nuclear translocation
were observed: 4.0% of cells for Ud and 29.6% of cells for PR8-
NS1. Following infection in the presence of ActD, however, the
level of nuclear translocation for both IRF3 and p65 dropped to
around 1% for both viruses, indicating that ActD efficiently inhib-
its activation and subsequent nuclear translocation of both of
these transcription factors.
Activation of the IFN induction cascade by influenza A virus
requires viral RNA synthesis and nuclear export. The inhibitory
effect of ActD on activation of the IFN induction cascade by in-
fluenza A viruses strongly suggested that viral polymerase activity
was required for this process. We next determined whether IRF3
activation was also sensitive to other inhibitors of viral RNA syn-
thesis. Alpha-amanitin inhibits bothRNApolymerase II initiation
and elongation (39) and thus, like ActD, prevents synthesis of viral
mRNA, cRNA, and vRNA (33, 34). In contrast, the RNApolymer-
ase II elongation inhibitor 5,6-dichloro-1--D-ribofuranosyl-
benzimidazole (DRB) (40, 41) does not affect primary viral tran-
scription but inhibits cRNA and vRNA synthesis (and therefore
secondary viral transcription) (42) by preventing the nuclear ex-
port of viral transcripts (23, 43). Consistent with previous publi-
cations, no viralmRNA, cRNA, or vRNA synthesis can be detected
in infected cells following treatment with either -amanitin or
ActD (Fig. 6A). Similarly, DRB impaired cRNA and vRNA syn-
thesis, but viral mRNA could still be detected under DRB treat-
ment conditions (at lower levels than in untreated cells, due to
impairment of vRNA synthesis and thus secondary transcription).
In situ hybridization experiments using a probe for NP mRNA
confirmed that ActD and -amanitin efficiently inhibited viral
mRNA synthesis and that DRB treatment did not prevent mRNA
synthesis but resulted in the retention of NP transcripts in the
nuclei of infected cells (Fig. 6B). Previous reports indicated that
DRB-mediated inhibition of mRNA nuclear export was a seg-
ment-specific effect that did not affect the export and subsequent
translation of NP mRNA; here, we clearly observe both nuclear
retention of NP mRNA (Fig. 6B) and efficient inhibition of NP
expression by DRB at the protein level (Fig. 7), indicating that
under these treatment and infection conditions DRB does inhibit
NPmRNAexport. These discrepancieswere not due to differences
in DRB concentration between this and previous studies, since we
observed the same inhibition of NP expression by DRB at much
lower concentrations of DRB (data not shown), but may instead
reflect cell-type-specific differences.
The effects of these inhibitors on IRF3 activation by influenza
virus were next examined. Consistent with data presented above,
phospho-IRF3 could clearly be detected under CHX treatment
conditions for cells infected with Ud, Ud-99, PR8, and PR8-
NS1 (Fig. 7A to D). In contrast, negligible IRF3 activation by
these viruses was detected in the presence of either -amanitin or
DRB, mirroring the effects of ActD treatment. Inhibition of IRF3
activation by these drugs was specific to influenza virus infections,
since they had no effect on IRF3 activation by PIV5-VC vM2
(Fig. 7E). Clearly then, the inhibitory effects of ActD on activation
FIG 3 Activation of IRF3 by influenza A viruses is sensitive to actinomycin D. A549 cells were infected with Ud (A), WSN (A), PR8 (B), Ud-99 (C), or
PR8-NS1 (D) at 5PFU/cell or left uninfected for 8 h in the presence CHX, ActD, or no drug. Cell lysates were prepared and subjected to SDS-PAGE and
immunoblotting for phospho-IRF3 (p-IRF3), total IRF3, viral proteins, and actin. (E) A549 cells were infected with PR8-NS1 at 5 PFU/cell or 55 PFU/cell. At
8 h p.i., cell lysates were prepared and treated as above. exp., exposure. (F)MDCK orMRC-5 cells were uninfected (UI) or infected with 5 PFU/cell of PR8-NS1
in the presence of ActD. At 8 h p.i., cell lysates were prepared and treated as above.
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of the IFN induction cascade by influenza A viruses also extend to
other inhibitors of viral RNA synthesis that possess different
modes of action.
That DRB, which blocks viral mRNA nuclear export but not
synthesis, functioned as a potent inhibitor of viral IRF3 activation
strongly suggested that bothRNA synthesis and nuclear export are
required for IFN induction by influenza virus under these exper-
imental conditions. While the high concentrations of ActD used
throughout this study inhibit primary viral transcription, lower
ActD concentrations do not; however, like DRB treatment, low
ActD concentrations limit secondary transcription and vRNA
replication by preventing the nucleocytoplasmic transport of viral
mRNA (23, 44). Within a concentration range of 0.25 to 0.75
g/ml of ActD, we observe nuclear retention of NP mRNA by in
situ hybridization; concentrations below this range do not prevent
cytoplasmic accumulation of mRNAs, while mRNA synthesis is
inhibited at concentrations above this range (Fig. 8A). Despite
viralmRNA synthesis proceeding at 0.5 and 0.75g/ml, therefore,
the viral mRNA is entirely nuclear in localization (Fig. 8A); at
these concentrations, no IRF3 activation was detectable (Fig. 8B).
Very small amounts of phospho-IRF3 are detectable at 0.25 g/
ml, which correlates with the appearance of a small proportion of
cells that exhibit cytoplasmicmRNA staining and subsequent syn-
thesis of low levels ofNPprotein. Further evidence for the require-
ment for both RNA synthesis and nuclear export for IFN induc-
tion comes from the observation that IRF3 activation induced by
Ud in the presence of CHX is sensitive to ActD or DRB, which
correlated with inhibition of RNA synthesis for the CHX/ActD
condition and with inhibition of RNA export for the CHX/DRB
condition (Fig. 8C and D). There is therefore a strong correlation
between the inhibitory effects of ActD, DRB, and -amanitin on
activation of the IFN induction cascade and their ability to inhibit
either viral RNA synthesis or nuclear export. Taken together, our
data indicate that, in this experimental system, input viral ge-
nomes do not function as a major PAMP and suggest instead that
synthesis and nuclear export of a viral RNA species (that is likely
distinct from progeny vRNPs) are required for activation of the
IFN induction cascade.
DISCUSSION
The requirements for viral replication and transcription activities
in the activation of the IFN induction cascade in cells infectedwith
influenza viruses have not been comprehensively studied previ-
ously.We have addressed these questions by examining activation
of the IFN induction cascade by influenza virus in the presence of
inhibitors of viral RNA synthesis. Unlike previous studies, we have
directly examined activation of endogenous components of the
IFN induction cascade within infected A549 cells, permitting us to
study the conditions under which PAMPs are generated by influ-
enza viruses in these cells.We clearly demonstrate activation of the
FIG 4 Actinomycin D-mediated inhibition of IRF3 activation is specific to
influenza virus infections. (A) A549 cells were transfected with poly(I·C) or
infected with Ud-99 or PIV5-VC vM2 at 5 PFU/cell in the presence or
absence of ActD. After 8 h, cell lysates were prepared and subjected to SDS-
PAGE and immunoblotting for phospho-IRF3 (p-IRF3), viral proteins, and
actin. Note that the increase in PIV5 NP expression in ActD treatment condi-
tions is due to inhibition of expression of cellular ISGs, likely ISG56, which is a
potent inhibitor of PIV5 protein synthesis (68). (B) A549 cells were infected
with 5 PFU/cell of Ud-99 or Sendai virus (SeV) Cantell in the presence or
absence of CHX or ActD. Cell lysates were prepared at 8 h p.i., subjected to
SDS-PAGE, and immunoblotted for p-IRF3, viral proteins, and actin. (C)
A549monolayers were uninfected or infected with Ud in the presence of CHX
and ActD or CHX alone. Two hours later, cells were fixed and input vRNPs
were detected using antibody to influenza virus NP. Nuclear material was
stained with DAPI (4=,6-diamidino-2-phenylindole). NP and DAPI staining
was visualized by fluorescence microscopy.
FIG 5 Inhibition of influenza virus-induced IRF3 and p65 nuclear transloca-
tion by ActD. A549 cell monolayers were infected with Ud or PR8-NS1 at 5
PFU/cell for 8 h in the presence of ActD. Uninfected cells and cells infected
with PIV5-VC vM2 (5 PFU/cell) were included as controls. Cells were then
fixed and immunostained using antibodies to IRF3 and p65. The nuclear lo-
calization of these transcription factorswas examined by fluorescence confocal
microscopy. The mean percentage of cells (1 standard deviation [SD]) ex-
hibiting nuclear IRF3 or p65 localization was quantified by scoring nuclear
localization from 10 fields of view from each condition; this is indicated on the
corresponding image for each condition.
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IFN induction cascade and transcription of IRF3-responsive genes
under conditions where viral protein synthesis and therefore the
generation of cRNPs and vRNPs are efficiently blocked by CHX
treatment or NP siRNA. It remains possible that inhibition of NP
synthesis by CHX and NP siRNA is not complete and that small
amounts of NP protein are being generated but are undetectable
by Western blotting. However, following these treatments we see
neither full-length progeny cRNA and vRNA by primer extension
analysis nor the synthesis of other viral proteins, indicating that
secondary transcription is effectively blocked. As such, these ex-
periments allow us to study the contribution of viral protein syn-
thesis and cRNP/vRNP synthesis to IFN induction and indicate
that full-length progeny genomes are not required for IFN induc-
tion in influenza virus-infectedA549 cells. In complete opposition
to our findings, a previous study identified progeny genomes gen-
erated during genome replication as the IFN-inducing PAMP
produced by influenza virus and even demonstrated that CHX
treatment of influenza virus-infected cells inhibited the accumu-
lation of “stimulatory” RNA (11). The experimental data on
which these conclusions were primarily based were a series of
experiments in which RNA was extracted from reconstituted
vRNPs and transfected back into cells along with an IFN- re-
porter plasmid; since RNA extraction strips the associated viral
nucleoprotein and polymerase from virus genomes, it would thus
be expected that the resultant unencapsidated genomes (that
would not normally be found in infected cells) would efficiently
activate the IFN response. Moreover, during vRNA synthesis, the
5= termini of newly synthesized progeny genomes are bound and
protected by a polymerase complex distinct from the replicative
polymerase (45) and should not be able to activate RIG-I. It
should be stressed, however, that while genome replication was
not essential for IFN induction in our experiments, we found that
IFN induction by PR8-NS1 was enhanced when genome repli-
cation was permitted to occur. This result may reflect the increase
in numbers of templates, possibly defective genomes (discussed
below), from which a PAMP can be generated when genome rep-
lication is permitted to occur. In support of this, IRF3 activation
by PR8-NS1 in the presence of CHX (but not in the presence of
ActD) can be considerably increased by increasing the amounts of
input virus (Fig. 3E). Alternatively, multiple types of PAMPs may
be generated by PR8-NS1, of which one or more may require
genome replication.
We additionally demonstrate that viral RNA synthesis is re-
quired for activation of the IFN induction cascade by influenza
viruses. In the presence of the cellular and viral transcription in-
hibitors ActD and -amanitin, we observed striking inhibition of
IRF3 phosphorylation and inhibition of IRF3 and p65 nuclear
translocation. This inhibitory effect correlated with inhibition of
viral polymerase activity since no viral RNA synthesis could be
detected in the presence of these drugs. While this article was in
preparation, it was reported that IFN induction by RNA viruses
did not require genome replication because RIG-I is activated by
incoming RNA virus nucleocapsids (46). While most of the sup-
porting evidence came from experiments using bunyaviruses, the
authors extended their conclusion to all viruses whose genomes
possess a 5=ppp dsRNA panhandle structure, including influenza
viruses.We demonstrate here that incoming vRNPs cannot be the
predominant inducer of IFN in influenza virus-infected A549
cells, since treatment with the transcription inhibitor ActD,
-amanitin, or DRB (which does not interfere with the entry and
nuclear import of incoming nucleocapsids) very effectively inhib-
its activation of the IFN induction cascade. Additionally, NS1, the
principal IFN antagonist of influenza viruses, is not present in the
virus particle and is expressed only following RNP nuclear import
and transcription; if incoming vRNPs acted as the predominant
RIG-I ligand, RIG-I would be activated prior to any NS1 expres-
sion and lead to IFN induction in every infected cell, a situation
that we have shown does not occur (47). However, while our data
rule out input vRNPs as a major PAMP in our experiments, we
could still observe IRF3 and p65 nuclear translocation in small
numbers (	1%) of infected cells in the presence of ActD. While
this may represent an incomplete block on viral RNA synthesis by
ActD, it may also be consistent with input viral genomes consti-
tuting a minor PAMP population that can induce IFN indepen-
dent of viral polymerase activity in a minority of cells. Although a
simple dsRNA panhandle structure formed by base pairing be-
tween the partially complementary termini of influenza vRNAs
was suggested by early studies, more-recent evidence favors a
more complex “corkscrew” conformation for vRNPs involving
the formation of short hairpin loops at each end of the vRNA
FIG 6 Viral RNA synthesis profiles in the presence of cycloheximide, actinomycin D, 5,6-dichloro-1--D-ribofuranosyl-benzimidazole, and -amanitin. (A)
A549monolayers were infectedwith PR8 at 5 PFU/cell in the presence of CHX, ActD,DRB,-amanitin (-Am; following a 1-h pretreatment of cells), or no drug
as indicated. Eight hours later, cells were harvested, and extracted RNA was subjected to primer extension analysis using 32P-labeled probes specific for PR8 NP
cRNA, vRNA, and mRNA. A further primer complementary to cellular 5S RNA was included as a loading control. (B) A549 cells were infected with Ud or PR8
at 5 PFU/cell in the presence of CHX, ActD,DRB,-amanitin (-Am; following a 1-h pretreatment of cells), or no drug as indicated for 8 h. Cells were then fixed,
and viral NP mRNA was visualized by in situ hybridization (red). Cell nuclei were stained with DAPI (blue).
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(48–53). While limited base pairing occurs within and between
the 3= and 5= ends in this structure, the proximal 9 or 10 nucleo-
tides of the termini do not bind each other to form dsRNA (1, 49,
54). Moreover, the vRNA termini are obscured in the presence of
polymerase (1), and despite the partial terminal complementarity
of vRNA segments, vRNPs behave as single-stranded RNA in the
absence of polymerase (12). The formation of the stretches of
exposed dsRNA with a 5=ppp that are required for efficient RIG-I
activation are thus precluded in this corkscrew structure (9, 10,
55). However, it has been reported that the 3= and 5= ends of naked
vRNA do base pair to form dsRNA (56, 57); such a product could
therefore activate RIG-I if it were generated as a result of errone-
ous replication.
The nuclear localization of RIG-I (or indeed any PRR) has not
hitherto been shown, yet it is thought that all influenza virus RNA
synthesis occurs in the nucleus. Thus, for an influenza virus RNA
to function as a PAMP and induce IFN, it must presumably be
exported to the cytoplasm, where it can activate RIG-I. Progeny
vRNPs translocate to the cytoplasm in order to be incorporated
into new virions, yet these are unlikely to be amajor RIG-I agonist
because we observe strong activation of the IFN induction cascade
under conditions where progeny vRNA is not synthesized. That
the IFN induction cascade is not activated when virus polymerase
activity is inhibited suggests two possible scenarios for the gener-
ation/exposure of the PAMP. The first is that limited polymerase
activity is required to displace RNA-associated proteins and ex-
pose input virus genome toRIG-I, but this is unlikely to be the case
since viral polymerase activity is thought to be restricted to the
nucleus and it is difficult to envisage how the input genome itself
could function as an efficient PAMP for the reasons outlined
above. Our data support a second scenario in which polymerase
activity is required to generate an RNA product (that is distinct
from progeny vRNA molecules) that translocates to the cyto-
plasm, where it can be recognized by RIG-I. Consistent with the
latter explanation is the observation that IRF3 activation is very
efficiently inhibited by DRB treatment and by low concentrations
of ActD. Under these conditions, viral mRNA synthesis was not
inhibited but viral transcripts were retained in the nucleus. Thus,
in this situation, the PAMPwould be generated by the polymerase
but would be unable to translocate to the cytoplasm and would
therefore be unable to activate RIG-I. The nature of this RNA
species and how it would activate the IFN response is unclear.
Although we have correlated activation of IRF3 with the synthesis
and export of viral mRNAs, normal transcripts are capped and
polyadenylated and should therefore be indistinguishable from
cellular transcripts in terms of RIG-I activation; if generated dur-
ing primary viral transcription, the PAMPwould therefore have to
be an aberrant transcription product. Unencapsidated cRNAs can
be generated by the polymerase in the absence of NP (58–62) but
are unstable in the absence of newly synthesized viral polymerase
and NP (24); these RNAs should possess the 5=ppp required for
RIG-I activation. These RNAs have been shown to be generated in
the presence of both CHX and ActD (24, 33) and so are presum-
ably also generated in the presence of DRB and -amanitin. If
these unencapsidated products are generated in the presence of
ActD, DRB, and -amanitin, however, they may still be retained
in the nucleus (thus preventing them from potentially activating
RIG-I) since these inhibitors also affect nuclear export of influ-
enza virus RNAs (Fig. 8) (23, 44).
In conclusion, we have demonstrated that RNA synthesis and
nuclear export are required for activation of the IFN induction
cascade by influenza viruses and that incoming vRNPs do not
therefore function as a major PAMP in this experimental system.
Furthermore, we suggest that the major viral PAMP is distinct
from progeny vRNPs since we observe activation of the IFN in-
duction cascade even in situations where the generation of prog-
eny vRNPs is inhibited.However, the exact nature of these PAMPs
still needs to be characterized. Our favored explanation, which we
are currently investigating, is that they are aberrant RNA prod-
ucts, perhaps produced by certain types of defective genomes.
FIG 7 Inhibition of influenza-induced IRF3 activation by actinomycin D,
5,6-dichloro-1--D-ribofuranosyl-benzimidazole, and-amanitin. A549 cells
were infected with Ud (A), PR8 (B), Ud-99 (C), PR8-NS1 (D), or PIV5-
VC vM2 (E) at 5 PFU/cell in the presence of CHX, ActD, DRB, -amanitin
(-Am; following a 1-h pretreatment of cells), or no drug as indicated for 8 h.
Cell lysates were then prepared and subjected to SDS-PAGE and immunoblot-
ting for phospho-IRF3, total IRF3, viral proteins, and actin.
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Intriguingly, defective viruses have been implicated in the induc-
tion of IFN by influenza A viruses previously (7, 63–65). Such a
scenario would be similar to that observed for paramyxoviruses,
whereby defective viruses are primarily responsible for IFN induc-
tion and can induce IFN in the absence of virus genome replica-
tion or protein synthesis (7, 19, 20, 35, 47, 66, 67). However, the
precise nature of the influenza virus PAMP and the stage of the
virus life cycle at which it is generatedmay differ depending on the
type of host cell being infected. Thus, it will be of great interest to
determine whether observations made in this study also extend to
other cell types, such as immune cells and plasmocytoid dendritic
cells, particularly given the critical role of the latter in IFNproduc-
tion during in vivo infections.
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